Encompass Health Corporation (NYSE:EHC) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 6.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 296,861 shares of the company’s stock after buying an additional 18,885 shares during the quarter. Envestnet Asset Management Inc. owned 0.29% of Encompass Health worth $30,066,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Encompass Health by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company’s stock worth $960,817,000 after buying an additional 138,196 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Encompass Health by 3.3% in the 4th quarter. Invesco Ltd. now owns 5,536,251 shares of the company’s stock worth $511,273,000 after purchasing an additional 176,135 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Encompass Health by 6.0% during the fourth quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company’s stock worth $191,799,000 after acquiring an additional 117,617 shares during the last quarter. FMR LLC increased its stake in shares of Encompass Health by 0.8% in the fourth quarter. FMR LLC now owns 1,973,846 shares of the company’s stock valued at $182,285,000 after purchasing an additional 15,831 shares during the period. Finally, Geode Capital Management LLC increased its position in Encompass Health by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company’s stock valued at $155,176,000 after acquiring an additional 6,164 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

Insider Transactions at Encompass Health

In other Encompass Health news, insider Elissa Joy Charbonneau sold 4,279 shares of the business’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the transaction, the insider directly owned 11,958 shares of the company’s stock, valued at approximately $1,394,422.38. The trade was a 26.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP John Patrick Darby sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the sale, the executive vice president directly owned 79,710 shares of the company’s stock, valued at approximately $9,149,910.90. This represents a 11.15% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 132,663 shares of company stock valued at $16,034,082. Corporate insiders own 2.10% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. KeyCorp upped their target price on Encompass Health from $122.00 to $135.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 27th. Wall Street Zen lowered shares of Encompass Health from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Royal Bank Of Canada raised their price objective on Encompass Health from $110.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, April 28th. Truist Financial restated a “buy” rating and set a $135.00 price target (up from $116.00) on shares of Encompass Health in a report on Monday, April 28th. Finally, Stephens upgraded Encompass Health from an “overweight” rating to a “strong-buy” rating and set a $135.00 price objective on the stock in a report on Thursday, June 5th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Encompass Health currently has a consensus rating of “Buy” and a consensus target price of $131.50.

Encompass Health Stock Up 1.0%

Shares of EHC stock opened at $119.64 on Tuesday. The stock has a 50 day moving average of $119.65 and a 200-day moving average of $106.55. The firm has a market cap of $12.06 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 2.41 and a beta of 0.88. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.81. Encompass Health Corporation has a 12 month low of $82.74 and a 12 month high of $123.13.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the previous year, the business posted $1.12 earnings per share. Encompass Health’s quarterly revenue was up 10.6% on a year-over-year basis. On average, equities analysts predict that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be paid a $0.17 dividend. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.57%. Encompass Health’s dividend payout ratio is presently 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.